Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$703.76 USD

703.76
1,303,782

-5.73 (-0.81%)

Updated Aug 6, 2025 04:01 PM ET

Pre-Market: $703.76 0.00 (0.00%) 8:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Thermo Fisher (TMO) Releases New Update for Omicron Detection

by Zacks Equity Research

Thermo Fisher's (TMO) TaqMan SARS-CoV-2 Mutation Panel currently offers direct identification of the novel variant of concern.

Zacks Equity Research

Medtronic (MDT) to Gain From Expanded Medicare Coverage for CGM

by Zacks Equity Research

CMS' expanded Medicare coverage includes continuous glucose monitors that can be integrated with Medtronic's (MDT) insulin pumps.

Zacks Equity Research

Exact Sciences (EXAS) Rides on Cologuard Sales Amid COVID Fear

by Zacks Equity Research

Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.

Zacks Equity Research

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Henry Schein's (HSIC) better-than-expected third-quarter results and robust performances by its operating businesses.

Zacks Equity Research

Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics' (DGX) strong third-quarter performance and raised guidance.

Zacks Equity Research

Here's Why You Should Hold on to Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Medtronic's (MDT) better-than-expected earnings in the fiscal second quarter and robust performance of the Diabetes arm.

Zacks Equity Research

Here's Why You Should Add LabCorp (LH) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about LabCorp's (LH) strong third-quarter 2021 results and raised guidance.

Zacks Equity Research

Avanos Medical (AVNS) Set to Acquire OrthogenRx for $160M

by Zacks Equity Research

Avanos Medical's (AVNS) deal to acquire OrthogenRx is likely to boost the company's chronic pain portfolio.

Zacks Equity Research

Here's Why You Should Invest in West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business.

Zacks Equity Research

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

Zacks Equity Research

Accuray's (ARAY) CyberKnife System Gets Shonin Approval

by Zacks Equity Research

Accuray's (ARAY) CyberKnife System can now be marketed in Japan post the Shonin approval.

Zacks Equity Research

Are Investors Undervaluing These Medical Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Here's Why You Should Retain Ecolab (ECL) Stock Right Now

by Zacks Equity Research

Ecolab (ECL) continues to gain traction from a solid product portfolio and segmental strength. However, segmental weakness remains a woe.

Zacks Equity Research

Veeva Systems' (VEEV) Buyout to Bolster Clinical Offering

by Zacks Equity Research

Veeva Systems' (VEEV) Veracity Logic buyout can help companies to simplify complex processes and speed up clinical trials.

Zacks Equity Research

McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Zacks Equity Research

McKesson (MCK) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

McKesson (MCK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

DENTSPLY SIRONA's (XRAY) New Alliance to Boost Digital Dentistry

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) and 3Shape extend their partnership to simplify digitally oriented workflows for dentists and dental technicians.

Zacks Equity Research

Here's Why You Should Retain Change Healthcare (CHNG) Stock

by Zacks Equity Research

Change Healthcare (CHNG) continues to benefit from robust payment accuracy business. However, intense competition remains a woe.

Zacks Equity Research

Best Growth Stocks to Buy for December 13th

by Zacks Equity Research

ARCB, CSV, and MCK made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 13, 2021.

Zacks Equity Research

Best Value Stocks to Buy for December 13th

by Zacks Equity Research

ABG, TPH, and MCK made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 13, 2021.

Zacks Equity Research

NEOGEN (NEOG) Inks Deal to Boost Global Genomics Business

by Zacks Equity Research

NEOGEN's (NEOG) latest acquisition of Genetic Veterinary Sciences, Inc. will bolster the global genomics business.

Zacks Equity Research

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from improving adoption of the da Vince Surgical System. Higher production costs are a woe.

Zacks Equity Research

OPKO Health (OPK) Receives FDA Nod for the 4Kscore Test

by Zacks Equity Research

OPKO Health (OPK) gets FDA nod for its 4Kscore Test that will further validate its value of being an important tool in the diagnosis of prostate cancer.

Zacks Equity Research

Are Investors Undervaluing These Medical Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

McKesson (MCK) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.